Answers are grounded in this paper and cite their sources.
PRODIGY showed that neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, is effective and tolerable in Korean patients with LAGC.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: